Reumatismo (Mar 2015)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?

  • M. Rossini,
  • O Viapiana,
  • G. Orsolini,
  • E. Fracassi,
  • L. Idolazzi,
  • D. Gatti,
  • S. Adami,
  • M. Govoni

DOI
https://doi.org/10.4081/reumatismo.2014.799
Journal volume & issue
Vol. 66, no. 4
pp. 285 – 303

Abstract

Read online

Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.

Keywords